Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Trials

Background:

• Atherosclerosis is a complex disease driven by risk factors like LDL-C.
• Cholesteryl-ester transfer-protein (CETP) regulates lipid levels, influencing LDL-C and HDL-C.
• CETP inhibitors (CETPis) represent a novel therapeutic strategy for atherosclerotic cardiovascular disease (ASCVD).

Purpose of the Study:

• To evaluate the efficacy of CETP inhibitors (CETPis) in reducing major adverse cardiovascular events (MACEs).
• To investigate the impact of CETPis on cardiovascular disease (CVD)-related and all-cause mortality.
• To synthesize findings from recent large-scale clinical trials on CETPis.

Main Methods:

• Conducted a meta-analysis of randomized controlled trials (RCTs) published between 2003 and 2023.
• Included studies comparing CETPi versus placebo with a minimum 6-month follow-up.
• Analyzed outcomes including MACEs, CVD-related mortality, and all-cause mortality.

Main Results:

• CETPi use significantly reduced CVD-related mortality (RR = 0.89; 95% CI: 0.81-0.98; p = 0.02).
• CETPi use significantly reduced the risk of myocardial infarction (MI) (RR = 0.92; 95% CI: 0.86-0.98; p = 0.01).
• These benefits were primarily attributed to anacetrapib; no significant effect on other outcomes was observed.

Conclusions:

• This meta-analysis provides the first evidence that CETPis are associated with reduced CVD-related mortality.
• CETP inhibitors demonstrate a significant reduction in myocardial infarction risk.
• Further investigation into specific CETPis like anacetrapib is warranted for ASCVD risk reduction.